Genetic risks of antiviral nucleoside analogues - A survey

Antiviral Research

Volumn 49, Issue 2, 2001, Pages 55-74

  Wutzler, Peter ^a   Thust, Rudolf ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Genotoxic effects; Nucleoside risks; Nucleosides; Risks

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CIDOFOVIR; DIDANOSINE; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PENCICLOVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; CANCER; CHO CELL; CHROMOSOME ABERRATION; DRUG CARCINOGENICITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; DRUG STRUCTURE; GENE MUTATION; GENETIC RISK; GENOTOXICITY; HERPES; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA L 5178 Y; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; RISK BENEFIT ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; ANTIVIRAL AGENTS; CARCINOGENICITY TESTS; CARCINOGENS; CHROMOSOME ABERRATIONS; HUMANS; MICE; MUTAGENICITY TESTS; MUTAGENS; NUCLEOSIDES;

RODENTIA;

EID: 0035250772     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00139-X     Document Type: Review

References (89)

1. Preclinical toxicology of zidovudine. An overview
2. Nonclinical studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rats
3. Children become the first victims of fallout
4. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives
5. Herpes simplex virus thymidine kinase gene-transfected tumor cells: Sensitivity to antiherpetic drugs
6. -) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and related compounds
7. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene
8. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells
9. UN acknowledges HIV/AIDS as a threat to world peace
10. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
11. Effects of (E)-5-(2-bromovinyl)-2′-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase deficient mouse cells
12. New antiherpes drugs in development
13. Sister chromatid exchange induced by anti-herpes drugs
14. 14C]BVDU in herpes simplex virus-infected cells
15. Preclinical toxicology studies with acyclovir: Genetic toxicity tests
16. A double-blind, placebo-controlled cytogenetic study of oral acyclovir in patients with recurrent genital herpes
17. Molecular aspects of anti-herpesvirus drugs
18. Suicide gene-mediated modulation of graft-versus-host diseases
19. Cell transformation assays as predictors of human carcinogenicity. The report and recommendations of ECVAM workshop 39
20. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
21. Lack of long-term effects of in utero exposure to zidovudine among children born to HIV-infected women
22. A history of antiherpes research
23. In search of the perfect antiviral
24. Trend in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses
25. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus)
26. Mutagenic potential of anti-herpes agents
27. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer
28. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice
29. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus (HSV-1), HSV-2, and varicella-zoster virus
30. A genetic model for colorectal tumorigenesis
31. Solution structure of a DNA decamer containing the antiviral drug ganciclovir: Combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement
32. Comparison of common gene mutation tests in mammalian cells in culture: A position paper of the GUM commission for the development of guidelines for genotoxicity testing
33. Genotoxic activity of azidothymidine (AZT) in in vitro systems
34. Protection against A2T-induced mutagenesis at the HGPRT locus in a human cell line by WR-151326
35. Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells
36. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-β-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase
37. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine
38. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay
39. Cell transformation by chemical agents - A review and analysis of the literature. A report of the U.S. Environmental Protection Agency Gene-Tox Program
40. Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES)
41. Different mechanisms of inhibition of DNA synthesis by of (E)-5-(2-bromovinyl)-2′-deoxyuridine in cells transfected with gene for thymidine kinase of herpes simplex virus type 1 and in cells infected with the virus
42. Cidofovir, a new agent with potent anti-herpesvirus activity
43. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine
44. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action
45. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy
46. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study group on gene therapy for glioblastoma
47. Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review
48. Deoxyribonucleoside triphosphate levels: A critical factor in the maintenance of genetic stability
49. The relationship between incorporation of (E)-5-(2-bromovinyl)-2′-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity
50. Revised methods for the Samonella mutagenicity test
51. Potent antiviral 5-(2-bromovinyl)uracil nucleosides are inactive at inducing gene mutations in Salmonella typhimurium and V79 Chinese hamster cells and unscheduled DNA synthesis in primary rat hepatocytes
52. Mutagenic and antimutagenic effects of 5-substituted 2′-deoxyuridines depending on the nature of the 5-substituent
53. Chiral chemical synthesis of DNA containing (S)-9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) and effects on thermal stability, duplex structure, and thermodynamics of duplex formation
54. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
55. Relationships between DNA incorporation, mutant freqencies, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine
56. Tumor chemosensitivity conferred by inserted thymidine kinase genes: Paradigm for prospective cancer control strategy
57. Lack of induction of micronuclei by azidothymidine (AZT) in vivo in mouse bone marrow cells
58. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
59. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′-dideoxythymidine
60. Immunofluorescent localization and quantitation of 3′-azido-2′,3′-dideoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster and mouse cell lines
61. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys
62. 3′-azido-3′-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT
63. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant woman, and cord blood from infants exposed in utero
64. Genotoxic properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU)
65. Induction of micronuclei in mouse bone marrow cells: An evaluation of nucleoside analogues used in the treatment of AIDS
66. A mammalian cell line designed to test the mutagenic activity of anti-herpes nucleosides
67. Pharmacokinetics of famciclovir in man
68. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
69. Carcinogenicity of 2′,3′-dideoxycytidine in mice
70. Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogues
71. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human α and human β polymerases
72. Superior cytotoxicity with ganciclovir compared to aciclovir and araT in HSV-TK-expressing cells: A novel paradigm for cell killing
73. The nonclinical toxicologic profile of stavudine
74. Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients
75. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
76. Monitoring of occupational exposure to cytostatic anticancer agents
77. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information
78. Genotoxicity of 3′-azido-3′-deoxythymidine in the human lymphoblastoid cell line, TK6: Relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT
79. Screening of potential chemical carcinogens by means of mammalian cells in vitro
80. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues
81. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in CHO cells transfected with the thymidine kinase gene of HSV-1: Implications for gene therapeutic approaches
82. Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: Comparison of ganciclovir, penciclovir and aciclovir
83. Preclinical studies with acyclovir: Carcinogenicity bioassays and chronic toxicity tests
84. Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line
85. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir
86. The mode of action of penciclovir
87. Deoxyribonucleotide analogs as inhibitors of DNA polymerases